Company: HROW
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001641172-25-006102
Chunk: 6

Company: HARROW, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 6
---
 until their successors are duly elected and qualified.

| Name                 |     | Age |     | Position & Committees                                                                                             |
| Mark L. Baum         |     |  52 |     | Chairman of the Board, Chief Executive Officer                                                                    |
| Adrienne L. Graves   |     |  71 |     | Independent Director, Audit Committee, Compensation Committee*, Nomination and Corporate Governance Committee*    |
| Lauren P. Silvernail |     |  66 |     | Independent Director, Audit Committee*, Compensation Committee, Nomination and Corporate Governance Committee     |
| Perry J. Sternberg   |     |  56 |     | Lead Independent Director, Audit Committee, Compensation Committee, Nomination and Corporate Governance Committee |

* Denotes committee chair.

Mark L. Baumis a founder, Chairman of the Board of Directors and Chief Executive Officer of the Company. In 2011, Mr. Baum led the restructuring and reorganization of the Company and since that time has directed the key operational and strategic activities of the Company. Mr. Baum was appointed as a director of the Company in December 2011, served as the Chairman of the Board of Directors from December 2011 to April 2012, was appointed Chief Executive Officer in April 2012, and was again appointed and has served as the Chairman of the Board since August 2021. Mr. Baum is also a founder and board member of Melt Pharmaceuticals, Inc. and is a founder and former board member of both Surface Ophthalmics, Inc., and Eton Pharmaceuticals, Inc. Before Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments in, and provided advisory and board service to, more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum actively advocates for patient and physician pharmaceutical accessibility issues, including being featured in Op-Ed contributions for the Wall Street Journal and appearances on national and international media outlets and other forums. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year TMin the life sciences category for the San Diego region. Mr. Baum serves on the board of the Ophthalmology Foundation, which works with eye care professionals to professional societies to enhance and provide ophthalmic education, focusing on low-resource and underserved countries. Mr. Baum is a graduate, cum laude, of The University of Texas at